Positive final results from the Phase III COSMIC-311 trial for Cabometyx (cabozantinib) were reported by Exelixis for patients diagnosed with previously treated radioactive iodine-refractory differentiated thyroid cancer.
The U.S. Food and Drug Administration approved Genentech and Blueprint Medicines’ Gavreto (pralsetinib) as a treatment for adults and pediatric patients 12 and older who have been diagnosed with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
Oncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.
Eli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
The U.S. Food and Drug Administration approved Novartis AG’s Tafinlar and Mekinist combination therapy to treat an aggressive type of thyroid cancer.
In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market.
Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
LOUISVILLE, CO–(Marketwired – August 04, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, a Tarmogen® product candidate targeting cancers that express carcinoembryonic antigen (CEA). GI-6207 is the second Tarmogen product candidate licensed by Celgene under the collaboration. Under […]